GenSight Biologics Reports Cash Position as of September 30, 2026

Paris, France, Wednesday, October 7, 2026, 11:55 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2026.

Cash Position and Early Access Programs as of September 30, 2026

GenSight Biologics’ cash and cash equivalents amounted to €0.7 million as of September 30, 2026, compared with €1.7 million as of June 30, 2026.

In the third quarter of 2026, the Company collected €1.7 million from the French named patient early access program (AAC). Total gross cash collections from paid early access programs reached €8.2 million since the start of treatments in March 2026.

The decrease in cash and cash equivalents over the quarter mainly reflects the summer pause in treatments under the AAC program in July and August, the continuation of the manufacturing technology transfer to Catalent, which was successfully completed at the end of September 2026, and the ongoing preparation of the RECOVER Phase III study.

Paid early access programs for GS010/LUMEVOQ^®[1] continue to generate cash inflows, supporting the Company’s operating activities. Treatments under paid early access programs in new countries are expected in Q4 2026. Collections are presented gross of rebates.

Funding Needs and Cash Runway

As previously disclosed on September 29, 2026, based on its current cash position and projected cash flows, the Company’s available financial resources are not sufficient to cover its operating requirements over the next twelve months. Early access collections and the research tax credit are expected to more than cover the Company’s operating expenses, and the net funding requirement is estimated at approximately €16 million, mainly corresponding to the costs of preparing the RECOVER Phase III trial and the associated manufacturing.

Assuming the Company secures, by the end of November 2026, either a short-term bridge financing of up to €2 million or cash inflows from additional early access treatments beyond those assumed in its projections, its cash resources would be sufficient until late March 2027, when the first significant payments for the preparation of the RECOVER trial fall due. Should the structural financing not be obtained by March 2027, the Company would postpone the start of the RECOVER trial; in that case, early access collections would continue to cover the Company’s operating expenses, subject to the timing of treatments and the continuation of the early access programs.

The Company’s funding requirements indicate the existence of a material uncertainty that may cast significant doubt on its ability to continue as a going concern, as described in Note 3.4 to the condensed half-year consolidated financial statements.

[1] GS010/LUMEVOQ^® is an investigational gene therapy that has not received marketing authorization in any country.